Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) just unveiled an announcement.
Shanghai Henlius Biotech, Inc. has announced that the China Securities Regulatory Commission (CSRC) has accepted its application for the H Share Full Circulation. This development will allow certain unlisted shares of the company to be converted into H shares, which will be listed and traded on the Main Board of the Hong Kong Stock Exchange. This move is expected to enhance the company’s market presence and liquidity, providing more opportunities for investors and potentially strengthening its position in the biopharmaceutical industry.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biotechnology company based in China, focusing on the development and commercialization of high-quality biologic medicines. The company operates primarily in the biopharmaceutical industry, offering products and services related to the research and production of therapeutic proteins and monoclonal antibodies.
Average Trading Volume: 1,431,220
Technical Sentiment Signal: Buy
Current Market Cap: HK$24.78B
See more data about 2696 stock on TipRanks’ Stock Analysis page.